Connecting Research and Experts with Journalists

• share
• favorite_border

Hip implants with a delta ceramic or oxidised zirconium head and highly crosslinked polyethylene liner or cup had the lowest risk of revision during the 15 years after surgery, a new study led by the University of Bristol has found.

• share
• favorite_border

Los fibromas uterinos son una condición común que afecta hasta al 80% de las mujeres a lo largo de su vida. Casi la mitad de estas mujeres experimentarán síntomas que afectarán su calidad de vida y fertilidad, incluido dolor intenso y anemia. Los fibromas uterinos son la principal razón para realizar la extirpación del útero a través de la histerectomía. Sin embargo, los investigadores de Mayo Clinic recomiendan alternativas de tratamiento mínimamente invasivas a la histerectomía en un artículo invitado sobre práctica clínica publicado en la New England Journal of Medicine.

• share
• favorite_border

Researchers at WashU Medicine have identified a possible way to make glioblastoma cells vulnerable to different types of immunotherapy. The strategy, which they demonstrated in cells in the lab, forces brain cancer cells to display targets for the immune system to attack. Their study was published in Nature Genetics.

• share
• favorite_border

Husker engineer Eric Markvicka is developing a new approach for detecting acute exacerbations of chronic conditions.

• share
• favorite_border

With the GOP gaining control of the Senate, a race has emerged between Sen. John Thune and Sen. John Cornyn to succeed Mitch McConnell as Senate Republican Leader. ...

• share
• favorite_border

Experts at the George Washington University are examining the future of artificial intelligence under a Trump administration. ...

• share
• favorite_border

President-elect Donald Trump has the chance to change federal courts for a generation. ...

• share
• favorite_border

TikTok Canada was ordered to dissolve their operations over national security concerns. ...

• share
• favorite_border

Researchers at the University of Michigan Rogel Cancer Center have discovered a key reason why some cancers do not respond to immunotherapy: A metabolite transporter within the tumor microenvironment that blocks a key type of tumor cell death integral to immune response.